A Zippelius
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
König D, Scharl S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild S, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet E, Hayoz S, Thierstein S, Betticher D, Ris H, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO Open 2022; 7:100455.
07.04.2022Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
07.04.2022ESMO Open 2022; 7:100455
König D P, Scharl Sylvie, Vuong D, Guckenberger M, Furrer Katarzyna, Opitz Isabella, Weder W, Rothschild S I, Ochsenbein A, Zippelius A, Addeo Alfredo, Mark M, Eboulet E I, Hayoz S, Thierstein S, Betticher D C, Ris H-B, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M
MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome
Tinguely M, Knuth A, Moch H, Probst-Hensch N, Renner C, Maurer R, Dommann-Scherrer C, Schmid U, Bittermann A, Cogliatti S, Curioni Fontecedro A, Rousson V, Korol D, Lopes B, Knights A, Jenni B, Zippelius A. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer science 2008; 99:720-5.
01.04.2008MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome
01.04.2008Cancer science 2008; 99:720-5
Tinguely M, Knuth A, Moch H, Probst-Hensch N M, Renner C, Maurer R, Dommann-Scherrer C, Schmid U, Bittermann A G, Cogliatti Sergio B., Curioni Fontecedro A, Rousson V, Korol D, Lopes B, Knights A, Jenni B, Zippelius A